Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis

• DOI: 10.1111/jce.12123
• Publication Date: 2013-02-22T17:05:06Z
• Authors: GRACE LIN; ANGELA DISPENZIERI; ROBERT KYLE; MARTHA GROGAN; PETER A. BRADY
• Keywords: Cardiac Amyloidosis; Sudden cardiac arrest

Cardiac amyloidosis (CA) is associated with increased risk of sudden cardiac arrest. Although ICD therapy improves survival in patients cardiomyopathy due to other etiologies, the benefit CA unclear large part limited data on precise mechanism arrest and selection for therapy.The objective was determine amyloidosis.We reviewed all implant indications, procedures, therapies, evaluated at Mayo Clinic between 2000 2009.A total 53 (33 AL, 10 senile, 9 familial, 1 AA) who underwent implantation were included. Indication primary prevention 41 (77%) secondary 12 (23%) patients. The rate appropriate shocks 32% first year observed almost exclusively AL patients, occurring 15 (12 amyloidosis, 2 AA). Appropriate more frequent prior or sustained ventricular arrhythmias (secondary indication), less presented decreased ejection fraction syncope.A high especially AL-type amyloidosis. However, did not translate into overall benefit, suggesting that might be candidates imprecise.